Article
Gastroenterology & Hepatology
Meng-Na Wu, Wen-Jie Zheng, Wen-Xin Ye, Li Wang, Ying Chen, Jie Yang, Deng-Fu Yao, Min Yao
Summary: The study showed that TUFT1 expression in HCC was significantly elevated, closely correlated with clinical features and patient survival. Interfering with TUFT1 transcription significantly inhibited proliferation, invasion, and metastasis of HCC cells, indicating TUFT1 may be a potential molecular target for inhibiting HCC growth.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Oncology
Zhixian Wu, Hongwei Cheng, Jie Liu, Shuaishuai Zhang, Minda Zhang, Fangzhou Liu, Yinghui Li, Qian Huang, Yi Jiang, Shaohua Chen, Lizhi Lv, Dongliang Li, Jin-Zhang Zeng
Summary: This study investigated the role and diagnostic significance of stanniocalcin 2 (STC2) in hepatocellular carcinoma (HCC). The results showed that STC2 was upregulated in both tumor and serum of HCC patients and its overexpression promoted HCC growth. Furthermore, serum STC2 levels could serve as an auxiliary biomarker for detecting early HCC.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2022)
Article
Biochemistry & Molecular Biology
Guoming Chen, Cheng Zhang, Danyun Li, Dongqiang Luo, Hui Liao, Peizhen Huang, Ning Wang, Yibin Feng
Summary: This study identified HAMP and FOS as predictors for HCC and PD-1 treatment prognosis, and developed a prediction model. HAMP was found to have a better ability to diagnose HCC and predict PD-1 treatment sensitivity. It was also positively correlated with immune cell infiltration and expression of immune checkpoints.
Article
Oncology
Marianna Szemes, Zsombor Melegh, Jacob Bellamy, Ji Hyun Park, Biyao Chen, Alexander Greenhough, Daniel Catchpoole, Karim Malik
Summary: Wilms' tumour (WT) is a common solid paediatric malignancy, with successful treatment in most cases, but poorer prognosis in cases with anaplastic histology. Studies have shown increased expression of MYCN in anaplastic WT, and its regulation of various genes and pathways. Further research on MYCN in WT could lead to potential targeted therapeutics for poor-prognosis cases.
Article
Genetics & Heredity
Xin Zhou, Jia-mi Huang, Tian-man Li, Jun-qi Liu, Zhong-liu Wei, Chen-lu Lan, Guang-zhi Zhu, Xi-wen Liao, Xin-ping Ye, Tao Peng
Summary: The diagnostic and prognostic significance of ATP binding cassette subfamily C (ABCC) genes in hepatocellular carcinoma (HCC) was assessed in this study. ABCC1, ABCC4, ABCC5, and ABCC6 were found to potentially serve as prognostic biomarkers in HCC, and prognostic models constructed with these genes showed satisfactory efficacy.
FRONTIERS IN GENETICS
(2022)
Article
Cell Biology
Zili Zhen, Zhemin Shen, Yanmei Hu, Peilong Sun
Summary: A novel signature consisting of 7 angiogenesis-related genes was established to predict the prognosis of HCC patients. Patients in the high-risk group had a poor prognosis, and the risk score was an independent predictor for overall survival. Functional enrichment analysis showed that these genes were enriched in pathways related to cell proliferation and mitosis, with significant differences in immune cell infiltration between the two risk groups.
Article
Cell Biology
Yi-Ren Lin, Wen-Jing Yang, Guo-Wang Yang
Summary: The PPM1G gene is upregulated in liver hepatocellular carcinoma (LIHC) and is associated with poor prognosis and the tumor immune microenvironment in LIHC patients.
Article
Oncology
Yi Bai, Jinyun He, Yanquan Ma, He Liang, Ming Li, Yan Wu
Summary: DNA repair plays a critical role in tumor progression and affects various aspects such as tumor mutational burden, genome stability, PD-L1 expression, immunotherapy response, and tumor-infiltrating lymphocytes. A prognostic model based on DNA damage response genes was developed for hepatocellular carcinoma (HCC), and patients were stratified according to their risk scores. The model accurately predicted survival rates and showed potential as an independent factor for HCC prognosis. Gene set enrichment analysis revealed enriched pathways in high-risk HCC, and potential molecular subtypes were identified based on DDR gene expression. This study provides novel insights into HCC prognosis and molecular mechanisms.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Shuxian Zhang, Hanjuan Gong, Hailun Xie, Zhimin Huangfu, Yi Tang, Ming Xiao, Ming Li, Qingshu Li, Yalan Wang
Summary: In this study, the expression and clinical significance of DNM1L in hepatocellular carcinoma (HCC) were investigated. It was found that DNM1L expression was significantly higher in HCC tissues compared to adjacent/normal liver tissues. High DNM1L expression was associated with poorer overall survival and disease-free survival in HCC patients. Furthermore, DNM1L was found to be involved in key metabolic pathways and the resistance to sorafenib therapy, as well as the infiltration of immune cells in the tumor microenvironment.
MOLECULAR CARCINOGENESIS
(2023)
Article
Biochemistry & Molecular Biology
Xing-Wei Xie, Shan-Shan Jiang, Xiang Li
Summary: The study showed that CLEC3B expression was decreased in HCC and correlated with poor prognosis and immune cell infiltration in tumors, suggesting a potential role of CLEC3B in modulating tumor immunity through immune cell infiltration adjustment.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Gang Chi, Jinhong Pei, Xueqing Li, Xujiong Li, Hui Pang, Jia Cui, Dongkai Wu, Gexi Qu, Yuan He
Summary: This study aimed to evaluate the role of SMYD5 in hepatocellular carcinomas (HCC). The results showed that high expression of SMYD5 was associated with worse prognosis in HCC patients. Further analysis revealed that SMYD5 upregulation in HCC cells was induced by promoter hypomethylation, and silencing SMYD5 inhibited cell proliferation, migration, invasion, and enhanced sensitivity to paclitaxel.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Jens Bauer, Natalie Koehler, Yacine Maringer, Philip Bucher, Tatjana Bilich, Melissa Zwick, Severin Dicks, Annika Nelde, Marissa Dubbelaar, Jonas Scheid, Marcel Wacker, Jonas J. Heitmann, Sarah Schroeder, Jonas Rieth, Monika Denk, Marion Richter, Reinhild Klein, Irina Bonzheim, Julia Luibrand, Ursula Holzer, Martin Ebinger, Ines B. Brecht, Michael Bitzer, Melanie Boerries, Judith Feucht, Helmut R. Salih, Hans-Georg Rammensee, Stephan Hailfinger, Juliane S. Walz
Summary: The DNAJB1-PRKACA fusion protein is identified as a source of immunogenic neoepitopes and a potential target for T cell-based immunotherapy in fibrolamellar hepatocellular carcinoma. Vaccination with DNAJB1-PRKACA-derived peptides induces long-lasting T cell responses and improves survival in a single-patient study.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Hongjun Yu, Chaoqun Wang, Shanjia Ke, Miaoyu Bai, Yanan Xu, Shounan Lu, Zhigang Feng, Baolin Qian, Yue Xu, Menghua Zhou, Zihao Li, Bing Yin, Xinglong Li, Yongliang Hua, Yongzhi Zhou, Shangha Pan, Yao Fu, Yong Ma
Summary: CFHR4 expression is decreased in hepatocellular carcinoma (HCC) and is significantly correlated with clinicopathological variables. CFHR4 may be involved in various biological functions and regulatory pathways in HCC, and is closely related to immune cell infiltration. High CFHR4 expression is associated with prolonged patient survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Liewang Qiu, Ke Zhan, Kija Malale, Xiaoling Wu, Zhechuan Mei
Summary: A novel peroxisome-related gene signature was identified for predicting overall survival in hepatocellular carcinoma patients, showing good prognostic performance. The signature was validated and found to be independently predictive of patient outcomes, suggesting its potential for improving personalized OS prediction in HCC.
Article
Gastroenterology & Hepatology
Lu Tian, Luqing Zhao, Karen Man-Fong Sze, Charles Shing Kam, Vanessa Sheung-In Ming, Xia Wang, Vanilla Xin Zhang, Daniel Wai-Hung Ho, Tan-To Cheung, Lo-Kong Chan, Irene Oi-Lin Ng
Summary: RalA is significantly up-regulated in HCC patients and associated with aggressive tumor behavior and poor prognosis. Its up-regulation is driven by copy number gain, while RalGAPA2 knockdown increases RalA activity. Tumors with down-regulated RalGAPA2 and up-regulated RalA display more aggressive behavior and poorer survival, with Ral inhibition showing potential as a therapeutic approach.
Article
Oncology
Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Satoru Kakizaki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada
Summary: This study demonstrates that the HCC-GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev, with a high score being associated with unfavorable prognosis in terms of disease progression and overall survival.
Article
Oncology
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada
Summary: This study compared the efficacy and safety of atezolizumab and bevacizumab in patients with viral and non-viral infection in clinical settings. The results showed that there were no significant differences in the response rate, disease control rate, progression-free survival, and 12-month survival rates between viral and non-viral-related HCC patients. No significant difference in treatment-related adverse events was found between the two groups. Atez/Bev demonstrated good efficacy and safety for HCC patients with both viral and non-viral infections.
Article
Biochemistry & Molecular Biology
Kozue Kanemitsu-Okada, Masanori Abe, Yoshiko Nakamura, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yohei Koizumi, Masashi Hirooka, Yoshio Tokumoto, Bunzo Matsuura, Mitsuhito Koizumi, Yoichi Hiasa
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide, and therapeutic strategies targeting multidirectional pathways are necessary. Fibrosis is closely related to prognosis, and B cell-activating factor (BAFF) is associated with NAFLD severity. This study found that BAFF plays a crucial role in the development of non-alcoholic steatohepatitis (NASH) and may be a promising therapeutic target for NASH.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Ryo Yano, Kana Hirooka, Makoto Morita, Yusuke Imai, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
Summary: Deep attenuation transducers (DAX) are a feasible and reliable method for liver stiffness measurement, especially for obese patients. Compared to conventional probes and other elastography methods, DAX can successfully measure liver stiffness at various skin-to-liver capsular distances.
JOURNAL OF MEDICAL ULTRASONICS
(2023)
Article
Oncology
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Tomomitsu Matono, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Summary: This study investigated the relationship between nutritional status, as determined by the prognostic nutritional index (PNI), and outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). The study analyzed 485 HCC patients treated with Atez/Bev. The results showed that a PNI >= 47 was significantly associated with improved overall and progression-free survival in these patients.
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Article
Gastroenterology & Hepatology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Junichi Watanabe, Aki Kato, Katsunori Kusumoto, Eiji Takeshita, Yoshio Ikeda, Naofumi Yamamoto, Yuka Saeki, Yoichi Hiasa
Summary: This study examined the association between exercise habits and irritable bowel syndrome (IBS) in a young Japanese population. It found that moderate frequency and intensity of exercise were both inversely related to IBS, and exercising with others also helped prevent IBS.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Hironori Ochi, Atsushi Hiraoka, Takaaki Tanaka, Toshie Mashiba, Hideko Ohama, Fujimasa Tada, Cao Fang, Toyoki Shimamoto, Michiko Amano, Nobuaki Azemoto, Masashi Hirooka, Tomoyuki Yokota, Yoichi Hiasa
Summary: This study aims to investigate the prognosis and recurrence after radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC) in different age groups. The results showed that patients aged 80 years and older had worse prognosis, but there were no significant differences in recurrence rates among the groups. For patients aged 80 years and older, in addition to the modified albumin-bilirubin index, performance status was also a significant factor affecting prognosis. Therefore, preoperative evaluation of performance status and management of other diseases could contribute to a prolonged prognosis in elderly patients with early-stage HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka, Norio Horiike, Yoshinori Tanaka, Atsushi Hiraoka, Fujimasa Tada, Hironori Ochi, Yoshiyasu Kisaka, Seiji Nakanishi, Sen Yagi, Kazuhiko Yamauchi, Makoto Higashino, Kana Hirooka, Makoto Morita, Yuki Okazaki, Atsushi Yukimoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa
Summary: In this study, a scoring system was developed to accurately predict the occurrence of hepatocellular carcinoma (HCC) after viral eradication with direct-acting antiviral (DAA) therapy using data from the optimal time point. The scoring system was developed based on factors at SVR12, including diabetes, the fibrosis-4 (FIB-4) index, and the alpha-fetoprotein level. This simple scoring system accurately evaluates HCC risk after DAA treatment.
SCIENTIFIC REPORTS
(2023)
Article
Urology & Nephrology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Kana Shiraishi, Yu Hashimoto, Kazuhiro Tange, Shogo Kitahata, Tomoyuki Ninomiya, Sen Yagi, Masakazu Hanayama, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Hideomi Tomida, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: This study aimed to investigate the association between serum albumin levels and erectile dysfunction (ED) in Japanese patients with ulcerative colitis (UC). The results showed an independent inverse association between serum albumin and severe ED in these patients.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Gastroenterology & Hepatology
Fujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada
Summary: The study found that Atez/Bev may be a viable treatment option for uHCC patients with EGV, as long as appropriate endoscopic treatment is carried out. Despite differences in certain liver function parameters between EGV and non-EGV groups, there was no significant variance in progression-free survival rates.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Urology & Nephrology
Yasunori Yamamoto, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Kana Shiraishi, Yu Hashimoto, Kazuhiro Tange, Masakazu Hanayama, Shogo Kitahata, Tomoyuki Ninomiya, Sen Yagi, Seiyuu Suzuki, Naozumi Shibata, Hidehiro Murakami, Katsuhisa Ohashi, Hideomi Tomida, Eiji Takeshita, Yoshio Ikeda, Yoichi Hiasa
Summary: This study investigated the association between nocturia and constipation in patients with ulcerative colitis (UC). The results showed that the severity of nocturia is positively associated with constipation.
Article
Oncology
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Solda, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Valentina Burgio, Fabio Piscaglia, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Summary: The study analyzed the clinical and laboratory characteristics of HCC patients treated with AB and identified potential prognostic factors. A composite score based on these factors showed higher sensitivity and specificity compared to individual variables. The score was validated in a lenvatinib-treated HCC population and showed that AB was more effective in high score patients. This study suggests that the score could help guide therapeutic choice between lenvatinib and AB.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
